Meanwhile, a new analysis by The Wall Street Journal shows the pharmaceutical giant Mylan, which has come under fire for hiking the cost of the life-saving allergy shot EpiPen by 400 percent in less than a decade, has the second highest executive pay in the entire U.S. pharmaceutical industry. In the last five years, Mylan has paid its top five executives nearly $300 million. That’s second only to the pharmaceutical company Regeneron, which over five years paid its top five executives more than $500 million.